In conclusion, the data from the literature show that CMG reduces pro-inflammatory cytokines such as IL-6 [89] and TNF-α [90] and increases the levels of interleukin-a17A [98], which is considered a protective key factor in the development and relapse of IBD. The gene discussed is IL6; the disease is inflammatory bowel disease.